These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29961337)

  • 21. Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer.
    Pavlakis N; Cooper C; John T; Kao S; Klebe S; Lee CK; Leong T; Millward M; O'Byrne K; Russell PA; Solomon B; Cooper WA; Fox S
    Pathology; 2019 Dec; 51(7):673-680. PubMed ID: 31668406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.
    Davare MA; Vellore NA; Wagner JP; Eide CA; Goodman JR; Drilon A; Deininger MW; O'Hare T; Druker BJ
    Proc Natl Acad Sci U S A; 2015 Sep; 112(39):E5381-90. PubMed ID: 26372962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of RAS family members confers resistance to ROS1 targeting drugs.
    Cargnelutti M; Corso S; Pergolizzi M; Mévellec L; Aisner DL; Dziadziuszko R; Varella-Garcia M; Comoglio PM; Doebele RC; Vialard J; Giordano S
    Oncotarget; 2015 Mar; 6(7):5182-94. PubMed ID: 25691052
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutical Options in ROS1-Rearranged Advanced Non Small Cell Lung Cancer.
    Stanzione B; Del Conte A; Bertoli E; De Carlo E; Revelant A; Spina M; Bearz A
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of Crizotinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with ROS1 Rearrangement or MET Alteration: A Systematic Review and Meta-Analysis.
    Vuong HG; Nguyen TQ; Nguyen HC; Nguyen PT; Ho ATN; Hassell L
    Target Oncol; 2020 Oct; 15(5):589-598. PubMed ID: 32865687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Small cell transformation in crizotinib-resistant ROS1-rearranged non-small cell lung cancer with retention of ROS1 fusion: A case report.
    Wu CH; Su PL; Hsu CW; Chu CY; Lin CC
    Thorac Cancer; 2021 Nov; 12(22):3068-3071. PubMed ID: 34623764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted therapies for ROS1-rearranged non-small cell lung cancer.
    Patil T; Simons E; Mushtaq R; Pacheco JM; Doebele RC; Bowles DW
    Drugs Today (Barc); 2019 Oct; 55(10):641-652. PubMed ID: 31720561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer.
    Roys A; Chang X; Liu Y; Xu X; Wu Y; Zuo D
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):679-688. PubMed ID: 31256210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Construction of crizotinib resistant models with CD74-ROS1 D2033N and CD74-ROS1 S1986F point mutations to explore resistance mechanism and treatment strategy.
    Sun R; Meng Y; Xu R; Li Y; Xu X; Li Z; Zuo D
    Cell Signal; 2023 Jan; 101():110497. PubMed ID: 36265718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ROS1 rearranged nonsmall cell lung cancer and crizotinib: An Indian experience.
    Noronha V; Chandrakanth MV; Joshi AP; Patil V; Chougule A; Mahajan A; Janu AK; Chanana R; Prabhash K
    Indian J Cancer; 2017; 54(2):436-438. PubMed ID: 29469073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular Simulation Studies on the Binding Selectivity of Type-I Inhibitors in the Complexes with ROS1 versus ALK.
    Tian Y; Yu Y; Shen Y; Wan H; Chang S; Zhang T; Wan S; Zhang J
    J Chem Inf Model; 2017 Apr; 57(4):977-987. PubMed ID: 28318251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Crizotinib in ROS1-rearranged non-small-cell lung cancer.
    Arnaoutakis K
    N Engl J Med; 2015 Feb; 372(7):683. PubMed ID: 25671265
    [No Abstract]   [Full Text] [Related]  

  • 33. Crizotinib in ROS1-rearranged non-small-cell lung cancer.
    Shaw AT; Solomon BJ
    N Engl J Med; 2015 Feb; 372(7):683-4. PubMed ID: 25671264
    [No Abstract]   [Full Text] [Related]  

  • 34. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
    Mazières J; Zalcman G; Crinò L; Biondani P; Barlesi F; Filleron T; Dingemans AM; Léna H; Monnet I; Rothschild SI; Cappuzzo F; Besse B; Thiberville L; Rouvière D; Dziadziuszko R; Smit EF; Wolf J; Spirig C; Pecuchet N; Leenders F; Heuckmann JM; Diebold J; Milia JD; Thomas RK; Gautschi O
    J Clin Oncol; 2015 Mar; 33(9):992-9. PubMed ID: 25667280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
    Katayama R; Kobayashi Y; Friboulet L; Lockerman EL; Koike S; Shaw AT; Engelman JA; Fujita N
    Clin Cancer Res; 2015 Jan; 21(1):166-74. PubMed ID: 25351743
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
    Zou HY; Li Q; Engstrom LD; West M; Appleman V; Wong KA; McTigue M; Deng YL; Liu W; Brooun A; Timofeevski S; McDonnell SR; Jiang P; Falk MD; Lappin PB; Affolter T; Nichols T; Hu W; Lam J; Johnson TW; Smeal T; Charest A; Fantin VR
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3493-8. PubMed ID: 25733882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lazarus Syndrome With Crizotinib in a Non-Small Cell Lung Cancer Patient With ROS1 Rearrangement and Disseminated Intravascular Coagulation.
    Brosseau S; Gounant V; Naltet C; Théou-Anton N; Cazes A; Smonig R; Neuville M; Khalil A; Mikail N; Meignin V; Bergeron A; Zalcman G
    Clin Lung Cancer; 2018 Jan; 19(1):e57-e61. PubMed ID: 28844392
    [No Abstract]   [Full Text] [Related]  

  • 38. ROS1 Kinase Inhibitors for Molecular-Targeted Therapies.
    Al-Sanea MM; Abdelazem AZ; Park BS; Yoo KH; Sim T; Kwon YJ; Lee SH
    Curr Med Chem; 2016; 23(2):142-60. PubMed ID: 26438251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An updated patent review of small-molecule ROS1 kinase inhibitors (2015-2021).
    Liu M; Dai J; Wei M; Pan Q; Zhu W
    Expert Opin Ther Pat; 2022 Jun; 32(6):713-729. PubMed ID: 35343863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ROS1-rearranged Non-small Cell Lung Cancer.
    Giustini NP; Bazhenova L
    Thorac Surg Clin; 2020 May; 30(2):147-156. PubMed ID: 32327173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.